(Q5984881)

Ibrutinib (English)

19 October 2016

C₂₅H₂₄N₆O₂

1 reference

Ibrutinib (English)

20 November 2016

C=CC(=O)N1CCCC(C1)N2C3=C(C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=NC=N3)N

1 reference

Ibrutinib (English)

20 November 2016

C=CC(=O)N1CCC[C@H](C1)N2C3=C(C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=NC=N3)N

1 reference

World Health Organisation international non-proprietary name

Ibrutinib (English)

20 November 2016

1 reference

14 February 2018

ibrutinib (English)

1 reference

ibrutinib (English)

medical condition treated

19 October 2016

leukemia

1 reference

central nervous system lymphoma

2 October 2018

1 reference

2 October 2018

mantle cell lymphoma

1 reference

Waldenström macroglobulinemia

2 October 2018

1 reference

chronic lymphocytic leukemia

2 October 2018

1 reference

2 October 2018

lymphoblastic leukemia

1 reference

graft-versus-host disease

2 October 2018

1 reference

2 October 2018

non-Hodgkin lymphoma

1 reference

2 October 2018

lymphoma

1 reference

2 October 2018

B-cell lymphoma

1 reference

diffuse large B-cell lymphoma

2 October 2018

1 reference

significant drug interaction

2 October 2018

aspirin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clopidogrel

1 reference

A reference set of clinically relevant adverse drug-drug interactions

eptifibatide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tirofiban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

abciximab

1 reference

A reference set of clinically relevant adverse drug-drug interactions

prasugrel

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ticagrelor

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rac-warfarin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

acenocoumarol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rivaroxaban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

apixaban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

imatinib

bone marrow failure

1 reference

A reference set of clinically relevant adverse drug-drug interactions

crizotinib

bone marrow failure

1 reference

A reference set of clinically relevant adverse drug-drug interactions

idelalisib

bone marrow failure

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

BLK proto-oncogene, Src family tyrosine kinase

enzyme inhibitor

1 reference

BMX non-receptor tyrosine kinase

17 August 2016

enzyme inhibitor

1 reference

17 August 2016

Bruton's tyrosine kinase

enzyme inhibitor

1 reference

imported from Wikimedia project

17 August 2016

pregnancy category

US pregnancy category D

1 reference

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category D

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Ibrutinib

last update

13 April 2018

protein kinase inhibitors

1 reference

5 March 2018

0 references

Ibrutinib

0 references

Identifiers

InChI

InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1

1 reference

Ibrutinib (English)

20 November 2016

2 references

Ibrutinib (English)

20 November 2016

ChEBI release 2020-09-01

CAS Registry Number

936563-96-1

2 references

ibrutinib (English)

20 November 2016

https://commonchemistry.cas.org/detail?cas_rn=936563-96-1

10 April 2021

1 reference

Ibrutinib (English)

20 November 2016

2 references

Ibrutinib (English)

20 November 2016

Reaxys registry number

13102252

1 reference

ibrutinib (English)

19 October 2016

mapping relation type

2 references

IBRUTINIB (English)

20 November 2016

International Chemical Identifier

InChI

InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1

1 reference

IBRUTINIB (English)

20 November 2016

2 references

inferred from InChIKey

Hazardous Substances Data Bank

1 reference

1 reference

28 October 2019

IBRUTINIB (English)

10 May 2021

1 reference

DSSTOX compound identifier

0 references

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.232.543

27 December 2018

ECHA Substance Infocard ID

(R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (Form I) (English)

quotation

CAS no.: 936563-96-1 (English)

100.232.543

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.232.543

27 December 2018

(R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (Form I) (English)

quotation

CAS no.: 936563-96-1 (English)

1 reference

Ibrutinib (English)

publication date

17 November 2015

1 reference

ibrutinib (English)

20 November 2016

1 reference

ibrutinib (English)

20 November 2016

1 reference

2 references

ibrutinib (English)

20 November 2016

MedlinePlus drug identifier

0 references

1 reference

ibrutinib (English)

20 November 2016

0 references

1 reference

1 reference

https://docs.openalex.org/download-snapshot/snapshot-data-format

ibrutinib (English)

19 October 2016

0 references

1 reference

28 October 2013

Microsoft Academic ID

0 references

1 reference

26 January 2022

1 reference

4IFG (English)

19 October 2016

1 reference

4RZ7 (English)

UK Parliament thesaurus ID

19 October 2016

446352

subject named as

Ibrutinib

0 references

UMLS CUI

C3501358

1 reference